(Q24201079)

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

A comparative study of controlled-release morphine (CRM) suspension and CRM tablets in chronic cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

A randomized, double-blind, multi-site, crossover, placebo-controlled equivalence study of morning versus evening once-daily sustained-release morphine sulfate in people with pain from advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

A double-blind, randomized, crossover comparison between single-dose and double-dose immediate-release oral morphine at bedtime in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Medical therapy of malignant nerve pain. A randomised double-blind explanatory trial with naproxen versus slow-release morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Placebo-blinded study of morphine sulfate sustained-release tablets and immediate-release morphine sulfate solution in outpatients with chronic pain due to advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS Contin XL) in cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Controlled release morphine tablets: a double-blind trial in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Intravenous morphine for rapid control of severe cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Morphine or oxycodone in cancer pain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

A comparative study of 2 sustained-release morphine preparations for pain in advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Controlled-release morphine in cancer pain. Is a loading dose required when the formulation is changed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Morphine and oxycodone hydrochloride in the management of cancer pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Immediate- or sustained-release morphine for dose finding during start of morphine to cancer patients: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Control of cancer-related pain with MS Contin: a comparison between 12-hourly and 8-hourly administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Oral controlled-release morphine sulfate. Analgesic efficacy and side effects of a 100-mg tablet in cancer pain patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, explorat

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Efficacy and tolerance of oral dipyrone versus oral morphine for cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

An assessment of the efficacy and tolerability of a 'double dose' of normal-release morphine sulphate at bedtime

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Choice of strong analgesic in terminal cancer: diamorphine or morphine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Opioid treatment for radiating cancer pain: oral administration vs. epidural techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

A randomized study on oral administration of morphine and methadone in the treatment of cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Clinical observations on controlled-release morphine in cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Oral tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Comparisons of the Analgesic Effects of Oral and Intramuscular Oxymorphone and of Intramuscular Oxymorphone and Morphine in Patients with Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, single-dose studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Patient-controlled analgesia for cancer pain: a long-term study of inpatient and outpatient use

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Low energy Helium-Neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Long-term treatment of cancer pain with transdermal fentanyl

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Dose-ranging study of oxycodone for chronic pain in advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Chronopharmacokinetic variability in plasma morphine concentrations following oral doses of morphine solution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Self-administration of morphine in bone marrow transplant patients reduces drug requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Patient-controlled analgesic infusions: alfentanil versus morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Cocaine and morphine interaction in acute and chronic cancer pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

The United States experience with oral controlled-release morphine (MS Contin tablets). Parts I and II. Review of nine dose titration studies and clinical pharmacology of 15-mg, 30-mg, 60-mg, and 100-mg tablet strengths in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Epidural and subcutaneous morphine in the management of cancer pain: a double-blind cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Use of strong opioids in advanced cancer pain: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Systemic absorption of nebulized morphine compared with oral morphine in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Management of cancer pain with oral controlled-release morphine sulfate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Double-blind evaluation of analgesic efficacy of orally administered diclofenac, nefopam, and acetylsalicylic acid (ASA) plus codeine in chronic cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Randomised trial of oral morphine for chronic non-cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Octreotide: a potent new non-opiate analgesic for intrathecal infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Nimodipine fails to enhance the analgesic effect of slow release morphine in the early phases of cancer pain treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Nimodipine-enhanced opiate analgesia in cancer patients requiring morphine dose escalation: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Peak plasma concentrations after oral morphine: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

The number needed to treat: a clinically useful measure of treatment effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Systematic review of factors affecting the ratios of morphine and its major metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Analgesic response to single and multiple doses of controlled-release morphine tablets and morphine oral solution in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Transdermal fentanyl for cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Controlled-release oxycodone and morphine in cancer related pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Size is everything--large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

"Evidence" in chronic pain--establishing best practice in the reporting of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Amitriptyline for neuropathic pain and fibromyalgia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

Evaluation of a cancer pain model for the testing of long-acting analgesics. The effect of MS Contin in a double-blind, randomized crossover design

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

Relative analgesic potency of oral zomepirac and intramuscular morphine in cancer patients with postoperative pain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

Comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

Steady-state kinetics and analgesic effect of oral morphine in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

Treatment of severe cancer pain by low-dose continuous subcutaneous morphine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

Developing a database of published reports of randomised clinical trials in pain research

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

The evaluation of analgesic effects in cancer patients as exemplified by a double-blind, crossover study of immediate-release versus controlled-release morphine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

Pharmacokinetics of two novel rectal controlled-release morphine formulations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

A double-blind, crossover trial of intravenous clodronate in metastatic bone pain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

Efficacy and pharmacokinetics of a new controlled-release morphine sulfate 200-mg tablet

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

Effects of oral morphine on cold pressor tolerance time and neuropsychological performance

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

Management of cancer pain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

Double-blind evaluation of short-term analgesic efficacy of orally administered diclofenac, diclofenac plus codeine, and diclofenac plus imipramine in chronic cancer pain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

Rescue factor: A design for evaluating long-acting analgesics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

Effects of inhaled nebulized morphine on ventilation and breathlessness during exercise in healthy man

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

A controlled study of sustained-release morphine sulfate tablets in chronic pain from advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

Comparison of morphine and ketorolac for intravenous patient-controlled analgesia in postoperative cancer patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

Morphine pharmacokinetics and effects on salivation and continuous reaction times in healthy volunteers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

The influence of the route of administration: a comparative study at steady state of oral sustained release morphine and morphine sulfate suppositories

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

Cervical versus thoracic epidural morphine for the treatment of head and neck cancer pain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

A novel morphine sulphate preparation: clinical trial of a controlled-release morphine suspension in cancer pain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

A randomized crossover study comparing the efficacy and tolerability of a novel once-daily morphine preparation (MXL capsules) with MST Continus tablets in cancer patients with severe pain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

Controlled-release oral morphine sulfate in the treatment of cancer pain with pharmacokinetic correlation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

Clinical efficacy and safety of a novel controlled-release morphine suppository and subcutaneous morphine in cancer pain: a randomized evaluation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021

A pharmacodynamic study of morphine and its glucuronide metabolites after single morphine dosing in cancer patients with pain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003868.PUB3

7 January 2021